UNITUXIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for UNITUXIN (UNITUXIN).
Dinutuximab is a chimeric monoclonal antibody that binds to the disialoganglioside GD2, which is overexpressed on neuroblastoma cells. Binding to GD2 induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
| Metabolism | Dinutuximab is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific CYP450 enzyme involvement. |
| Excretion | Unchanged drug: negligible renal excretion; metabolism and biliary/fecal elimination are the primary routes. Specific % not established; in clinical studies, <1% of dose recovered in urine as parent drug. |
| Half-life | Terminal half-life approximately 22.6 days (range 11.4–45.3 days) in pediatric patients; supports every-other-week dosing. Half-life is prolonged compared to adults due to slower clearance in children. |
| Protein binding | Approximately 99.7% bound to human serum proteins; primarily binds to albumin and beta-2-glycoprotein I. |
| Volume of Distribution | Estimated Vdss approximately 4.5 L (not weight-normalized; corresponds to ~0.06 L/kg in a 70 kg adult) indicating limited extravascular distribution. |
| Bioavailability | Only intravenous administration; bioavailability 100% by IV route. |
| Onset of Action | Intravenous: Clinical effects (inhibition of GD2-mediated tumor growth) observed within 2–3 weeks after initiation of therapy; not applicable for immediate symptom relief. |
| Duration of Action | Pharmacodynamic effects persist for several weeks after last dose due to long half-life; clinical duration of response varies by tumor type and combination therapy. No standard duration defined. |
| Molecular Weight | 147500 |
1,500 mg/m² intravenously over 1 hour on days 1, 8, and 15 of each 28-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; use caution in severe renal impairment (CrCl < 30 mL/min) due to limited data. |
| Liver impairment | No specific dose adjustment for Child-Pugh Class A or B; not studied in Child-Pugh Class C. |
| Pediatric use | Weight-based dosing: for patients ≤ 30 kg, 1,500 mg/m²; safety and efficacy not established in pediatric patients < 18 years. |
| Geriatric use | No specific dose adjustment; elderly patients may have increased risk of infusion-related reactions and renal impairment. |
| 1st trimester | Limited data; monoclonal antibodies are known to cross placenta in increasing amounts after first trimester. Use only if potential benefit justifies potential risk to fetus. |
| 2nd trimester | Monoclonal antibodies cross placenta more readily; risk of fetal immune modulation. Use only if clearly needed. |
| 3rd trimester | Highest placental transfer; may cause fetal B-cell depletion and potential for neonatal infection. Avoid unless necessary. |
Clinical note
Comprehensive clinical and safety monograph for UNITUXIN (UNITUXIN).
| Placental transfer | Dinutuximab is a monoclonal antibody (IgG1), which is known to cross the placenta, especially during the second and third trimesters, with increasing transfer as pregnancy progresses. Evidence suggests significant fetal exposure. |
| Breastfeeding | Not known if dinutuximab is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, advise patients to discontinue breastfeeding during treatment and for at least 6 months after last dose. |
■ FDA Black Box Warning
No FDA black box warning exists for dinutuximab.
| Serious Effects |
Severe hypersensitivity to dinutuximab or any excipientsActive life-threatening infectionsSevere hepatic impairment (AST/ALT > 10x ULN, or total bilirubin > 3x ULN) prior to treatment
| Precautions | Severe neuropathic pain requiring opioid analgesia; premedicate with opioids., Capillary leak syndrome, which may be life-threatening., Hypotension, hypertension, and tachycardia; monitor vital signs., Peripheral neuropathy including sensory and motor deficits., Serious infections, including sepsis., Reversible posterior leukoencephalopathy syndrome (RPLS)., Infusion-related reactions including anaphylaxis. |
| Food/Dietary | No specific food interactions are known. Maintain adequate hydration. Grapefruit products should not be avoided unless specified by other medications. Manage electrolyte imbalances as needed, but no dietary restrictions. |
Loading safety data…
| Lactation Rating | L4 (Probably Unsafe) |
| Teratogenic Risk | Unituxin (dinutuximab) is a monoclonal antibody (IgG1) that can cross the placenta. Based on its mechanism of action (GD2-directed), it is expected to cause fetal harm. In animal studies, administration during organogenesis resulted in embryolethality and structural abnormalities. First trimester: Avoid exposure due to risk of teratogenesis. Second/Third trimester: Risk of fetal GD2-positive tissue destruction; may cause fetal neurotoxicity and autonomic dysfunction. Contraindicated in pregnancy. |
| Fetal Monitoring | Monitor for maternal infusion reactions, hypotension, capillary leak syndrome, and neurotoxicity. Fetal monitoring: Ultrasound for growth and amniotic fluid volume; assess for fetal hydrops or structural anomalies if exposure occurred. Newborns should be evaluated for persistent GD2 antibody binding and potential autonomic dysfunction. |
| Fertility Effects | In animal studies, dinutuximab did not directly impair fertility, but chronic inflammation and immune modulation may indirectly affect reproductive function. In humans, no dedicated fertility studies are available. Patients should be counseled about potential effects on ovarian or testicular function, especially with prolonged use. |
| Clinical Pearls | Unituxin (dinutuximab) is a monoclonal antibody targeting GD2 ganglioside on neuroblastoma cells. Premedicate with antihistamines, acetaminophen, and IV fluids to reduce infusion reactions. Monitor for severe neuropathic pain, which may require opioid analgesics and dose interruption. Risk of capillary leak syndrome, hypotension, and hyponatremia; check vital signs and electrolytes frequently. Administer in a specialized oncology setting with resuscitation equipment available. |
| Patient Advice | Unituxin is given intravenously over 10-20 hours. You will receive medicines before infusion to reduce side effects. · Common side effects include severe pain, fever, low blood pressure, and allergic reactions. Report any chest tightness, difficulty breathing, or severe abdominal pain immediately. · You may experience nerve pain; this can be managed with pain medications. Do not drive if you are taking opioid pain relievers. · Drink plenty of fluids unless instructed otherwise. Your urine output will be monitored. · This drug can cause fluid retention; report rapid weight gain or swelling of legs or feet. · Avoid live vaccines while on this therapy and for at least 6 months after treatment. · Do not become pregnant or father a child during treatment; use effective contraception. |